Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12946289 | 0.82 | PDPK1 (0.39) | PDPK1NPC1PKMMAPK1 | |
| SCHEMBL25172583 | 0.77 | PDPK1 (0.36) | PDPK1NPC1PKMMAPK1 | |
| SCHEMBL25167501 | 0.77 | PDPK1 (0.36) | PDPK1NPC1PKMMAPK1 | |
| SCHEMBL30401838 | 0.74 | PDPK1 (0.34) | PDPK1NPC1PKM | |
| SCHEMBL25169370 | 0.74 | PDPK1 (0.34) | PDPK1NPC1PKM | |
| SCHEMBL31373050 | 0.74 | PDPK1 (0.34) | PDPK1NPC1PKM | |
| SCHEMBL31373005 | 0.72 | PDPK1 (0.33) | PDPK1MAPK1 | |
| SCHEMBL30434128 | 0.72 | PDPK1 (0.36) | PDPK1 | |
| SCHEMBL23104538 | 0.69 | PDPK1 (0.43) | PDPK1GPR35NPC1PKMMAPK1 | |
| SCHEMBL25169405 | 0.68 | PDPK1 (0.35) | PDPK1GPR35NPC1PKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747261-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | Accutar Biotechnology Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250084095-A1 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | ACCUTAR BIOTECHNOLOGY INC. | 2025-03-13 | — | — | US | disclosed |
| WO-2025024388-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | CDK6, CDK2, CDK8 | PDPK1 78/4885GPR35 4166/4885NPC1 3954/4885 |
| US-20250084095-A1 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | CDK6, CDK2, CDK8 | PDPK1 78/4885GPR35 4166/4885NPC1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.